

Index

- Abbreviated New Drug Application (ANDA), 93
- Acquisitions, 54-57
 defined, 8
 foreign participation in, 54-56
 of independent seed companies, 108
 premium paid for stock during, 57
 See *also* Consolidation
- Advisory Board for Biological Safety (ZBKS)-Germany, 191
- Advisory Committee on Genetic Modification (ACGM)--
 United Kingdom, 193
- Advisory Committee on Release to the Environment (ACRE)-
 United Kingdom, 193
- Agriculture
 biopesticides for, 102-103, 105-106
 biotechnology-related R&D directed toward, 10,11,103-105,
 108, 109-110
 biotechnology's commercial applications to, 8-10, 11, 100-
 107
 cell culture and, 104-105
 environmental applications of biotechnology to, 8-10, 11,
 103-105, 108, 109-110, 129-131
 public opinion on biotechnology applied to, 10, 112-113
- Agricultural Research Service (ARS)--USDA, 104
- AgriGenetics, 109
- Agrocere SA, 108,109
- AIDS (acquired immunodeficiency syndrome), biotechnology
 research to combat, 76-77,78, 79
- Alcohol, Drug Abuse, and Mental Health Administration
 (ADAMHA), conflict of interest regulations of, 24
- American Bionetics, Inc., 124
- American Cyanamid Co.
 consolidations by, 57
 diversification by, 123
 product marketing arrangements by, 8
- Amgen, 88,92
 cost of biotechnology products of, 84
 financing strategies, 6,48,49,50,56,59,61,63
 product marketing arrangements by, 80
- Animal and Plant Health Inspection Service (APHIS), deliberate
 release regulation by, 179, 180
- Applied Biosystems, 156
- Applied Biotechnology, 124
- Ares-Serono Group, 57
- Argentina
 food exports by, 112
 intellectual property protection in, 92
 seed company subsidiaries in, 108
- Asgrow Seed Co.
 acquisition of, 109
 patent infringements and, 110
- Asia
 consolidations involving companies in, 55
 public opinion of agricultural biotechnology, 10, 112-113
 strategic alliances involving companies in, 58,59,60,61
 See *also* individual countries in
- Australia
 pharmaceutical cost-containment in, 84
 plant patenting in, 110
 research policies and regulation in, 15, 151
 seed company subsidiaries in, 108
- Austria, 108
- Bacillus thuringiensis (BT), 113
 gene transferred to plant, 105, 106-107
 use in biopesticides of, 102-103
- Bager, 89
- Bangu Pharmaceutical, 85
- Belgium
 biotechnology infrastructure in, 21
 centralized waste treatment facilities in, 135
 patent term extension proposal in, 93
- Biogen, financing strategies used by, 47
- Bio-oriented Technology Research Advancement Institution,
 156-157
- Biopesticides
 agricultural use of, 105-106
 approval of Mycogen's, 103
 market for, 102-103
- BioProbe International, Inc., 124
- Bioremediation
 advantages of, 136-137
 case study, 131-140
 constraints on use of, 12,40
 environmental protection laws effect on use of, 40
- Biotechnica International Diversification of, 109
- Biotechnology
 in chemical industry, 120-122
 commercial activity overview, 3-12, 29-32,39-41
 defining, 3,5,29,33
 environmental applications of, 129-140
 intellectual property rights in, 208-210
 in pharmaceutical industry, 73-94
 policy overview concerning industrial commercialization of,
 13-19,31-32, 147
 products under development, 79
 as a singular coherent entity, 3,31,39
- Biotechnology Development Center (BIDEC), 157
- Biotechnology Directorate (U.K.), 160
- Biotechnology General Corp, 124
- Biotechnology Joint Research Association, 153
- Biotechnology Research for Industrial Development and
 Growth in Europe (BRIDGE) program, 104
- Biotechnology Research Subcommittee (BRS)-OSTP, 23,174
- Biotechnology Science Coordinating Committee (BSCC)-
 OSTP, 22-23
 interagency agreements concerning regulatory policy and,
 173, 176
 See *also* Biotechnology Research Subcommittee
 "Black Monday"
 effect on biotechnology financing of, 6-7,46,47, 51,54
 See *also* Financing; Wall Street
- Boehringer-Mannheim Corp., 60,89
- Bovine somatotropin (bST), 102, 190-191, 194, 1%
 farmer resistance to, 40
 See *also* Agriculture; Pharmaceuticals
- Boyer, Herbert, 56

- Brazil
 food exports by, 112
 intellectual property protection for pharmaceuticals in, 92-93
 pharmaceutical cost-containment policy in, 84
 regulation of biotechnology in, 15
 seed company subsidiaries in, 108
Bristol-Myers Squibb Corp., 88
Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure, 207
Burroughs Wellcome Co., 60,82
Bush, George (President), 177
- Calgene, Inc.
 diversification of, 109
 product approval requested by, 183
California
 DBC's in, 89
 deliberate release protests in, 188
California Biotechnology, Inc., 89
Canada, 51
 animal vaccine development and approval in, 101
 biohydrometallurgy program in, 131
 intellectual property protection in, 92-93
 pharmaceutical cost-containment policy in, 84
 seed company subsidiaries in, 108
Canadian Center for Mineral and Energy Technology, 131
Cancer, biotechnology research on, 76
Capital
 variations in cost of (international), 6,50,51-53
 See *also* *Costs*; *Economics*; *Financing*
Cardo, 109
Cargill, 109
Celanese Research Co., 123
Cellular Products, 124
Center for Biologics Evaluation and Research (FDA), 75,90
Center for Drug Evaluation and Research (FDA), 75
Centocor
 FDA product regulation and, 79
 marketing alliance by, 84,85
Cetus Corp.
 FDA regulatory decision effect on, 79,90
 marketing alliance by, 89
 merger *with* Chiron, 6, 54
 Proleukin export by, 91
chemical industry, 119-124
 biotechnology's commercial applications in, 10-12, 120-122
 restructuring of, 10-11,40, 122-124
 See *also* *Industry*
Chile, 108
Chiron Corp.
 financing strategies and market value of, 48-49
 merger with Cetus by, 6, 54
Chugai Pharmaceutical, Inc., 7,54,57,89
Ciba-Geigy Corp., 58,59,60,82,89,108
Cistron, 124
Clause Co., acquisition of, 109
Clean Water Act (CWA), 138
Commercialization
 activity concerning biotechnological, 3-12,29-32,39-41
 barriers to bioremediation, 137-139
 congressional options to promote biotechnology, 22
 factors affecting biotechnology, 31,32
 national (worldwide) policies effecting biotechnological, 13-19,31-32, 147, 151,
152, 161-166,169
 U.S. policy effects on industrial biotechnological, 151, 152,
161-166,169
 U.S. policy concerning technology transfer and
 biotechnological, 166-167,169
Competitiveness, 19-21,39,41
 European industrial biotechnology commercialization's, 21
 Japanese industrial biotechnology commercialization's, 19-
21
 prerequisites for biotechnology, 14
 U.S. industrial biotechnology commercialization's, 19
 See *also* *Commercialization*
Comprehensive Environmental Response, Compensation,
 Liability Act (CERCLA), 138
Congress, U.S.
 global biotechnology competitiveness interest by, 32
 Orphan Drug Act amendment attempt by, 92
 policy options for, 21-25
 USDA basic research finding increase by, 111
Consolidation
 of seed companies, 108
 trends in biotechnology, 6-7,53-57
 See *also* *Acquisitions*
Containment
 EC regulations covering, 192
 of genetically altered micro-organisms, 177-178
 NIH Guidelines for, 173,174, 186
Coordinated Framework for Regulation of Biotechnology, 180
 OSHA Guidelines in, 178, 179
 product approval under, 15-16
 regulation under, 22, 184, 186
Corporate relationships. See *Acquisitions*; *Consolidation*;
 Strategic alliances
costs
 bioremediation, 136
 pollution cleanup, 131, 139-140
 of receiving a U.S. patent, 215-214
 See *also* *Economics*; *Financing*
Crick, Francis H.C., 31
Crop Genetics International, Inc. (CGI), 103
Cytel Co., 89
Cytogen Corp., 124
- Dedicated biotechnology companies (DBC's)
 acquisition of U.S. pharmaceutical, 87,88
 agreements with established pharmaceutical companies for
 marketing by, 84-85
 capital acquisition methods of U.S., 3-6,7,39,50-51,53
 consolidation trends of, 6-7,53-57, 87, 88
 patent piracy problems of, 19, 110,223
 strategic alliances' use by U.S., 88-89
 tax law changes to aid, 24-25
 venture capital available for, 3-6,7,39, 50
DeKalb Seed Co., 108
Denmark
 biotechnology regulation development in, 15,40, 189
 centralized waste treatment facilities in, 135
 pharmaceutical cost-containment policy in, 84
 public opinion of agricultural biotechnology, 10

- research policies in, 151
- Department of Agriculture, U.S. (USDA)
 plant genome mapping program, 104
 product approval by, 15
 regulation of plants and animals for food by, 172, 180
- Department of Commerce, U.S. (DOC), 119
- Department of Energy, U.S. (DOE)
 genome project funding by, 104
 MEOR incentives of, 131
- Department of Health and Human Services, U.S. (DHHS)
 biotechnology regulation by (proposed), 24
 FDA review by, 90
 See **also** *commission's* and programs under jurisdiction of d'Estaing, Giscard, 159
- Developed countries. See Industrialized nations
- Developing countries
 difficulty in meeting regulatory requirements by, 186
 field-tests in, 112
 food exports by, 112
 See **also** Newly Industrializing Countries; individual countries
- Development. See Commercialization
- Diamond v. Chakrabarty, importance** and effects of, 16,209, 214,223
- Dow chemical Co., diversification by, 123
- Dow Jones Industrial Average. See Black Monday; Wall Street
- DNA Plant Technology Corp.
 agricultural cell culture R&D by, 105
 diversification by, 123
- Drugs. See Pharmaceuticals
- Drug Export Amendments Act of 1986,91
- Drug Price Competition and Patent Term Restoration Act of 1984,93
- du Pont & Nemours Co., E.I.
agricultural cell culture R&D by, 105
 diversification by, 123, 124
- Eastman Kodak Co., 59
- Economics
 of bioremediation's commercialization, 139
 of biotechnology companies (worldwide), 6,45-53
 of consolidation involving biotechnology companies, 53-64
 of resource use, 12
 See **also** Costs; Financing
- Elf Aquitaine Corp. diversification by, 124
- Eli Lilly & Co.
 acquisitions by, 88
 licensing deals by, 80
- Enimont Corp., diversification by, 124
- Environment
 applications of biotechnology to, 12,129-140
 planned introductions of genetically altered micro-organisms into, 21, 177-182
- Environment and Gene Technology Act (EGTA)--Denmark, 189
- Environmental Protection Agency (EPA)
 bioremediation use by, 139
Exxon Valdez cleanup involvement by, 134
 micro-organism regulation by, 15-16, 17,23, 172, 181
 pesticide regulation by, 102-103, 172, 181
 regulation of field testing by, 40
 waste disposal R&D conducted by, 137
- Ernst & Young, biotechnology survey by, 45,50,82,88
- Erythropoietin (EPO)
 orphan drug status and profitability of, 92
 price of, 84
 See **also** Pharmaceuticals
- Europe
 animal vaccine development and approval in, 101
 biotechnology programs in, 160-161, 162,163-164
 biotechnology regulation and promotion policies in, 14, 15, 21,40,112,151, 152,191-194
 chemical industry in, 10, 123-124
 food exports from, 112
 intellectual property protection for plants in, 110
 national technology policies in, 14, 151, 152, 158-160
 pharmaceutical market competition by, 21,85
 pollution cleanup costs in Western, 131
 public opinion of biotechnology in, 10,40, 112
 seed trade by, 108
strategic alliance Use in, **58,59,60,61, 89**
 See **also** *European Community*; individual countries in European Community (EC)
 biotechnology programs in, 160-161, 162,163-164
 biotechnology promotion in, 14, 152
 biotechnology regulation in, 15,21,112\$191-194
 bST moratoriums in, 102
 contamination inventories in countries of, 135-136
 financial-related information on countries in, 50,52-53
 food exports by, 112
 gene mapping work by, 104
 market for drugs in, 85
 pharmaceutical patent term extension legislation in, 93
 See **also** Europe; **member countries of**
- European Patent Convention (EPC), requirements of, and rights protected under, 208**
- Experimental Use Permit (EUP), 179,180**
- Exxon Valdez**
 bioremediation project, 134
 public attention on bioremediation after oil spill in, 129
- Federal Coordinating Council on Science, Engineering, and Technology (FCCSET), 176
- Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA), deliberate release regulation under, 16, 179, 180
- Federal Meat Inspection Act, U.S., 184
- Federal Register, 23**
- Federal Trade Commission (FTC), 56
- Field tests
 countries performing agricultural biotechnology-related, 10, 11
 EPA regulation of U. S., 15-16, 17,40
 See **also** Agriculture; Regulation
- Financial Accounting Standards Board (FASB), 25
- Financing
 biotechnology R&D strategies, 45-53
 biotechnological environmental cleanup research efforts, 137, 139, 140
 congressional options for biotechnology research, 21-22
 German biotechnology, 160
 Japanese biotechnology research and development, 154,155, 157, 158
 overview of biotechnology, 3-7
 supporting microbiological mining, 131

- Swiss biotechnology, 160
 U.S. Government R&D, 3,19,20,21-22,111,131, 137,140
 See *also* Costs; Economics
- Food
 biotechnological applications to processing, 107
 uses of transgenic animals, 184-186
 uses of transgenic plants, 182, 183
- Food and Drug Administration (FDA)**
 basis of biotechnology-based product regulation authority by, 15, 16,22,76, 107, 111, 176-177
 biotechnology-based drug approval process of, 7,56,75-78, 79
 bST approved by, 102
 L-tryptophan recall by, 120
 orphan drug approval by, 92
 regulation effects on financial status of DBCs, 52,75-76,78, 79
 regulation of plants and animals as food, 173, 176-177, 178, 182
 regulatory delay's effect on biotechnology-based industry, 75-76,78,79,90-91
 review by HHS,90
- Food, Drug, and Cosmetic Act (FDCA), FDA regulation of biotechnology products under, 15,16,22,76, 107, 111, 176-177, 183
- Food Safety and Inspection Service (FSIS), 185, 186
- France
 biotechnology infrastructure in, 21
 biotechnology policy in, 159
 biotechnology regulations in, 15, 193
 biotechnology R&D in, 83, 135
 patent term extension proposal in, 93
 pharmaceutical cost-containment policy in, 84
 seed company subsidiaries based in, 108
- Fresh World Venture, 105, 123
- Fuji Film, 156
- Funai Pharmaceuticals Co., Ltd., 123
- Funding. See Financing
- Funk Seed Corp., acquisition of, 108
- Garst Co., consolidation activity by, 108
- Gen-Probe, Inc., acquisition of, 54,57,89
- Genentech
 biotechnology product pricing by, 84
 FDA regulatory decision's effect on, 90
 financing strategies and market value of, 47,48,49,50,53,80
 merger with Hoffmann-La Roche by, 6, 54, 56, 57, 82, 89
 Ministry of Health and Welfare (Japan) grant to, 156
 product marketing arrangements by, 80
- General Agreement on Tariffs and Trade (GATT), 217-218,224
 patent law harmonization effort using, 23-24
 pharmaceutical industry protection under, 91
 See *also* Regulation
- Generally recognized as safe (GRAS), 177,182**
- Genetic Systems, 54,57,88**
- Genetic Technology Law (Germany), 190**
- Genetics Institute, Inc., merger by, 48,89,92**
- Genex, Inc., merger by, 47**
- Genofit SA, 124**
- Genzyme Corp., proposed takeover by, 57**
- Germany
 biotechnology infrastructure in, 21
 biotechnology policy and regulation in, 15,40, 160,189
 biotechnology R&D funding in, 83, 135
 centralized waste treatment facilities in, 135
 Green Party's strength in, 186-187
 pharmaceutical market competition by, 83,85
 public opinion of biotechnology commercialization in, 10,40, 186, 187
 seed company subsidiaries in, 108
- Gilead Sciences, 89
- Gist-Brocades, Inc., industrial enzyme production by, 121
- Glaxo, InC.
 multilateral nature of, 81, 82
 R&D investments by, 93
 strategic alliance use by, 89
- Goodwill, amortizing, 25,67
- Goodwill Industrial Large-Scale Practice (GILSP), 180, 195
- Government, U.S. See United States
- Granulocyte colony stimulating factors. See Pharmaceuticals
- Greece, pharmaceutical cost-containment in, 84
- Green parties, makeup, policies, and opinions of biotechnology by, 186-187
- Gross national product (GNP)
 chemical industry and, 122
 See *also* Wall Street
- Growth hormones. See Human growth hormone
- Guidelines**
 NIH laboratory safety, 174, 195.
 NIH standards as basis for industrialized nations', 173, 174, 175
 technology transfer, 165
 See *also* Regulation
- Hansens Co., industrial enzyme production by, 121
- Harmonization. See Intellectual property; Patents**
- Hawaii, deliberate release regulation in, 188**
- History**
 of chemical industry growth rate compared to GNP, 122
 of seed companies, 108
 of U.S. commercial biotechnology, 45-48
- Hitachi Corp., second-generation genome sequencer, 156**
- Hixson, Harry, 61**
- Hoechst Chemical Corp., diversification by, 123**
- Hoffmann-La Roche, Inc.**
 licensing deals by, 80
 mergers by, 6,7,48,56,57,82, 89
 multilateral nature of, 82
- Holden's Foundation Corn Seeds, 108**
- Human growth hormone**
 orphan drug status and profitability of, 92
 price of, 84
 See *also* Pharmaceuticals
- Human immunodeficiency virus (HIV). See Acquired immunodeficiency syndrome**
- Hybrids**
 developing new, 107, 110
 RFLP techniques for producing, 103, 104
 seed, 109, 110
 See *also* Agriculture; Plant breeders' rights
- Hybritech, InC., 88**

- ICI Chemical Corp.
 diversification by, 123-124
 seed company subsidiaries of, 108
- Illinois, deliberate release regulation in, 188
- Immunex Corp., product marketing arrangements by, 80
- Immunomedics, Inc., 89
- Incentives
 bioremediation product development, 140
 biotechnological R&D, 64-66,91-93
 intellectual property protection, 91-93
 investment and cooperation in biotechnology, 64-66,153-154
 microbial enhanced oil recovery use, 131
- India
 intellectual property protection in, 92
 seed company subsidiaries in, 108
- Industrialized nations
 agricultural applications of biotechnology in, 9-10
 biotechnology regulation in, 14-15, 188-195
 financial health of biotechnology companies in, 50-64
 food exports by, 112
 See *also* **Newly Industrializing Countries; individual nations**
- Industry**
biotechnology as a singular, coherent, 3,31,39
case study of seed, 107-112
congressional options for improving university relationships with, 24
consolidation within, 53-64
facility location and regulation of European, 16
financing and market values of "biotechnology", 46-53
international biotreatment, 135-136
Japanese weakness in biotechnology-related sectors of, 20
policy concerning biotechnology's commercialization by, 13-19,31-32, 147
R&D focus of "biotechnology", 4546
U.S. biotreatment, 132-135
 See *also* Commercialization; individual industries
- In re Durden, 220-221*
- Institute* for Immunology (Japan), DBC investment by, 89
- Institute of Life Sciences, 153
- Institute of Molecular and Cell Biology, 154
- Integrated Genetics, Inc., 57
- Intellectual property protection, 203-224
 agricultural-related, 110
 biotechnology commercialization and, 16-19,208-210
 congressional options concerning; 23-24
 international agreements concerning, 205-208
 See *also* individual forms of
- Interleukin II
 export of, 91
 FDA regulatory decision on, 90
 See *also* Pharmaceuticals
- International agreements
 on intellectual property, 205-208
 See *also* individual conventions, treaties
- International Trade Commission (ITC), 24, 219
- International Union for the Protection of Plant Varieties (UPOV), requirements of, and rights provided under, 110, 207-208
- Investigational New Drug (IND) application, 76
- Italy
 biotechnology regulation in, 14-15
 pharmaceutical cost-containment in, 84
 pharmaceutical R&D funding by, 83
 seed company subsidiaries in, 108
- Japan, 151**
 biotechnology promotion and commercialization in, 13-14, 19-21, 152
 biotechnology regulation development in, 15,40,91, 192
 chemical industry in, 120-121, 123, 124
 consolidation activity in, 88
 economic growth policies of, 84, 152, 153, 155, 158
 economics of biotechnology companies in, 50,53
 government-industry relations in, 157-158
 market penetration in, 85, 86, 91
 pharmaceutical industry in, 83,84,85,86,88
 pharmaceutical patent-term extension legislation in, 93
 plant patenting in, 110
 public opinion of biotechnology in, 10, 112-113
 research in, 83, 155
 seed company subsidiaries in, 108
 strategic alliances use in, 89
 waste treatment in, 135
- Japan Association of Industrial Fermentation, 157
- Japan Development Bank, 20, 154
- Japan Health Sciences Foundation, 156-157
- Japan Research Development Corp. (JRDC), 156
- Johnson & Johnson, 59,82,88
- Key Technology Center, 157
- Keyworth, George, 164
- Korea, South, biotechnology policy& research in, 13-14, 154
- Korea Genetic Research Association (KOGERA), 154
- Latin America**
 seed trade in, 108
 See *also* individual countries in
- Legislation
 bioremediation-relevant, U.S., 138
 biotechnology-related, 15,214
 patent term extension, 93
 process patent protection (proposed), 24
 See *also* **individual statutes**
- Limagrain, 108**
- Litigation**
biotechnology-related, 219,220,223
financial drain from patent-related, 19
 See *also* individual cases
- Lubrizol Enterprises
 diversification by, 124
 seed company acquisition by, 109
- Market-Oriented Sector-Selective (MOSS) talks, 86
- Massachusetts General Hospital, 123
- Max Planck Institute (Germany), 191
- Medicaid, 84
- Medicare, 83,84,92
- Medicare Pharmaceutical and Prudent Purchasing Act, 84
- Merck & Co., Inc.
 licensing deals by, 80,89
 multinational nature of, 82
- Merck Frosst, 93
- Mergers. See consolidation
- Merrill (U.S.), 123

- Mexico, 108**
- Microbial Enhanced Oil Recovery (MEOR), state of and challenges to, 131, 132**
- Midwest Plant Biotechnology Consortium (MPBC), 166**
- Mining, microbiological, 131**
- Ministry of Agriculture, Forestry, and Fisheries (MAFF)-Japan**
 biotechnology support by, 156-157
 field testing regulated by, 111
 gene mapping work by, 104
- Ministry of Education, Science and Culture (MESC)--Japan, biotechnology support by, 153, 154-155**
- Ministry of Health and Welfare (MHW)--Japan, biotechnology support by, 86, 156**
- Ministry of International Trade and Industry (MITI)--Japan**
 biotechnology initiatives of, 19-20, 153-154
 biotechnology's targeting by, 11-12, 19, 120-121, 154
 industry-government cooperation and, 157-158
 Next Generation projects of, 153
- Minnesota, bST moratorium in, 102**
- Missouri, deliberate release protests in, 188**
- Mitsubishi chemical Industries, agricultural cell culture R&D by, 105**
- Mitsubishi Kasei Corp., 153**
- Mitsubishi Knowledge Industry, 156**
- Mitsui Toatsu Chemical Co., agricultural cell culture R&D by, 105**
- Molecular Biosystems, Inc., 124**
- Molecular Genetics**
 diversification by, 124
 original genetically engineered vaccine introduced by, 101
- Monosodium glutamate (MSG), 120**
- Monsanto Agricultural Co.**
 diversification by, 123-124
 relationship with Oxford University by, 160
- Morita, Katsura, 157**
- Morocco, 108**
- Mycogen**
 biopesticide development by, 103
 financing strategies used by, 48
- Nakasone (Prime Minister Japan), 155**
- National Biotechnology Policy Board, 177**
- National Institute of Agrobiological Resources, 157**
- National Institute of Genetics (Japan), 154**
- National Institutes of Health (NIH)**
 basic research funding by, 21-22, 164-165
 bST safety confirmed by, 102
 conflict of interest regulations of, 24
 genome project funding by, 104
 laboratory-safety guidelines of 173, 174, 195
 recombinant DNA—Advisory Committee (RAC), 173
- National Program in Biotechnology-Singapore, 154**
- National Research Initiative, 111**
- National Science Foundation (NSF), genome project funding by, 104**
- National Technical Information Service (NTIS), 32**
- Netherlands, The, 15**
 pharmaceutical cost-containment in, 84
 seed company subsidiaries in, 108
 waste treatment research by, 135
- New Developments in Biotechnology: Patenting Life, 23**
- New Developments in Biotechnology: U.S. Investment in Biotechnology, 24,74**
- New Drug Application (NDA)--PTO, 76,93**
- Newly Industrializing Countries (NICs)**
 biotechnology promotion and research policies of, 151-152
 biotechnology regulation in, 14, 188-189
 contaminated areas in, 135-136
 economic growth policies of, 152, 154
 intellectual property protection in, 92
 See *also* individual countries
- Nippon Telephone & Telegraph, 157**
- Northrup King, 109**
- Nova Pharmaceutical Corp., 89**
- Novo-Nordisk, industrial enzyme production by, 121**
- Office of Management and Budget (OMB), role in BSCC**
 dissension of, 176
- Office of Scientific and Technical Policy (OSTP)**
 BSCC and BRS formation by, 23, 176, 181
 regulatory policy promulgated by, 15
- Office of Technology Assessment (OTA), 5,23,29,31**
 biotechnology funding conclusions in reports by, 151, 152
 international competitiveness measurement by, 19,20
 planned introduction report by, 131
 workshops and conferences conducted by, 32-33
- Okazaki National Research Institute (Japan), 154-155**
- Omnibus Budget Reconciliation Act of 1990,25,66**
- Organization of Economic Co-operation and Development (OECD)**
 basis of differences in biotechnology regulation in, 194
 EC biotechnology directives based on recommendations by, 191-195
 waste treatment R&D in countries of, 135-136
 See *also* individual member nations of
- Organization of Petroleum Exporting Countries (OPEC), 122**
- Orphan Drug Act**
 biotechnology products and, 91,92
 cost-containment and, 83, 84, 85
 intentions of, 40
 tax credits and, 66-67
 See *also* Pharmaceuticals
- Ortho Biotech, 88**
 FDA product regulation and, 79
 licensing deals by, 80
- Oxford University, 160**
- Pacific Rim countries. See Newly Industrializing Countries**
- Paris Convention for the Protection of Industrial Property, 206**
- Patents**
 biotechnology protection under, 17-18,203-204,205,210-223
 farmers exemptions to, 222-223
 harmonization of procedural requirements worldwide for, 18-19,23-24,203-204
 legislation affecting, 18-19,23-24,93
 piracy of U.S., 19,213-214
 plant protection using utility, 205
 requirements for, objectives of, and protection offered by, 203-204
 See *also* Intellectual property protection
- Patent and Trademark Office, U.S. (FTO)**
 application backlog effects, 16-17,212-124

- See **also** Intellectual property protection; Patents
 Patent Cooperation Treaty (PCT), requirements of and rights provided by, 206-207
- Personnel
 brain-drain of experienced English biotechnology, 160
 shortage of trained bioremediation, 139
- Pesticides
 nonchemical, nonrecombinant, 102-103
 recombinant, 105-106
 regulation of genetically engineered, 173, 179, 181
- Pfizer, Inc., 107
- Pharmaceutical industry, 7-16
 acquisition activity in, 7-8,9, 10,54-59,85-87
 biotechnology used in, 73-94
 characteristics, 7,10, 81-82
 Japan's, 85,86, 156
 multinational nature of, 81-82
 regulation of, 89-91
 strategic alliance use by, 88-89
- Pharmaceutical Manufacturer's Association (PMA),
 biotechnology-derived drug survey by, 75-78,79
- Pharmaceuticals
 approval of biotechnology-based, 75,76-78
 cost-containment and, 83, 84, 85
 marketing, 81,85,86
 orphan drug status and price of, 84, 85
 patent term extension for, 93
 planned use of recombinant, 178-179
 price manipulation in Japan of, 156, 158
 See **also** Pharmaceutical industry
- Philippines, 108
- Pioneer Hi-Bred International, 108, 109
- Planned introductions
 criteria for risk assessment of, 179
 of genetically altered micro-organisms, 178-182, 183
 of plant pest derivatives, 179
 of transgenic animals, 182
 of transgenic plants, 182-183
 of vaccines, 178-179
 regulation of, 189
 See **also** Regulation
- Plant breeders' rights, 110,204-205
- Plant Genetic Systems
 hybrid development by, 110
 transfer of insecticide resistant gene by, 106
- Plant genome projects, 103,104
- Plant Patent Act of 1930, requirements for and protection under, 110,204
- Plant Pest Act (PPA), deliberate release regulation under, 179, 180
- Plant Quarantine Act (PQA), deliberate release regulation under, 179, 180
- Plant Variety Protection Act of 1970 (PVPA)
 intentions of, 40, 110
 requirements of and protection under, 31,204-205
- Policy
 categories of, and examples of national biotechnology R&D, 152-166
 national regulatory, 186-195
 options concerning industrial commercialization of biotechnology for Congress, 21-25,41
 overview of biotechnological industrial commercialization, 13-19,31-32, 147
 overview of biotechnological R&D, 13-14, 147
 U.S. national, in a global environment, 166-167
- Pollution
 control using biotechnological techniques, 129, 134
 See **also** Toxic waste
- Poultry Products Inspection Act, 184
- Praxis Biologic
 American Cyanamid's takeover of, 57
 product marketing arrangements by, 80
- Product License Application (PLA), 76
- Protein Engineering Research Institute (PERI), 153, 157,158
- Provisional Council for Educational Reform (Japan), 155
- Public Health Service (PHS)--(DHHS), 24
- Public Opinion of risks and ethics of biotechnology-related R&D, 10,40, 112-113, 129, 136-137, 186, 187
- Quayle, Dan (Vice President, U.S.) 176,177
- Raab, Kirk, 56
- Recombinant DNA Advisory Committee (RAC), 173
- Regeneron Pharmaceuticals, 7
- Regulation
 agricultural, 111
 bioremediation commercialization and, 138-139
 congressional options for developing industrial biotechnology, 22-23
 of contained uses of micro-organisms, 177-178
 effect on competitiveness of, 14-16, 111, 195-196
 national policies for, 186-195
 pesticide, 103-104,173, 179,181
 pharmaceutical industry, 89-91
 planned release, 178-182, 183, 189
 State biotechnology-related, 180
- Remet, 107
- Repligen, Inc., 89
- Research
 associations (Japan), 157
 biotechnology-related product, 3-7,21-22,45-46,79,154, 155, 157,158
 congressional options for funding biotechnology, 21-22
 environmental applications of biotechnology, 131-132, 134-135, 137, 139-140
 funding biotechnology, 45-68
 importance of Japanese cooperative, 157, 158
 Japanese search for access to foreign, 20
 microbiological mining, 131
 problems with bioremediation, 137
 regulation's effect on locating facilities for, 16
 seed industry, 109-110
 types of, 31
 U.S. Government biotechnology, 3,19,20,21-22, 111, 131, 137, 150
- Research and development (R&D). See Commercialization; Research
- Research and Development Limited Partnerships (RDLPs),
 biotechnology investment using, 53
- Research and Development Tax Credit, 24-25,64-67
- Research base
 French, 159
 German, 160
 Japanese, 153, 155, 156

- relative strength of European, Japanese, and United States, 20, 40
- Swiss, 160-161
- United Kingdom's, 160
- Resource Conservation and Recovery Act (RCRA), 138
- Restriction fragment length polymorphism (RFLP) analysis, plant breeding using, 103, 104
- Rhone-Poulenc
- diversification by, 124
 - seed company acquisition by, 108-109
- Risk assessments
- biotechnological, based on similar technologies, 14
 - See *also* Guidelines; Regulation
- Roche Holdings, Ltd., acquisition of Genentech by, 56,82,89
- Rohm & Haas
- diversification by, 123
 - industrial enzyme production by, 121
- Royal Dutch-Shell, diversification by, 124
- San Diego, 31
- Sandoz, Inc.
- diversification by, 124
 - in-home biotechnology expertise by, 89
 - intellectual property protection's effect on R&D investment by, 93
 - seed company acquisition by, 109
- Sanofi (France), 88
- Schering AS, 57
- Schering-Plough Corp.
- acquisitions by, 57
 - licensing deals by, 80
- Science and Technology Agency (STA)--Japan, biotechnology support by, 153, 156
- Seiko, human genome mapping research by, 156
- Shearson Lehman Hutton, survey of biotechnology use in companies, 4849,50,51,58,59
- Showa Denko (Japan), 120
- Singapore
- biotechnology policies of, 154
 - biotechnology promotion in, 13-14
 - regulation in, 14-15
- Small Business Finance Corp. (Japan), 20, 154
- SmithKline Beckman, merger by, 82
- SmithKline Beecham PLC, licensing deals by, 80
- South Africa, biohydrometallurgy program in, 131
- South Korea, regulation in, 14-15
- Spain
- regulation in, 14-15
 - seed company subsidiaries in, 108
- Standard industrial classification (SIC), 119
- Standards. See Guidelines; Regulation; individual agencies'
- Standard and Poors 500. See Financing; Wall Street
- Start-up companies. See Dedicated biotechnology companies
- States
- biotechnology regulation by individual, 188
 - See *also* individual States
- Stauffer Seeds, 109
- Stoneville, acquisition of, 109
- Strategic alliances
- European companies use of, 58,59,60,61,89
 - increased use of, 57-60
 - types of and trends in, 8,57-67
- U.S. pharmaceutical DBCs' use of, 88-89
- Strategies. See Policy
- Subsidies
- European Community agricultural, 161
 - See *also* incentives
- Superfund Amendments and Reauthorization Act (SARA), 138
- Supplementary protection certificate (SPC), 93
- Swanson, Robert, 56
- Switzerland
- biotechnology infrastructure in, 21
 - biotechnology policy of, 160-161
 - pharmaceutical firms in, 81,82,83,85
- Synergen, 124
- Syntex Corp., multinational nature of, 82
- System for Promotion of Exploratory Research for Advanced Technology (ERATO), 156, 158
- T Cell Sciences, Inc., 89
- Taiwan
- biotechnology promotion in, 13-14, 154
 - regulation in, 14-15
- Takeda, 153
- Tanox Biosystems, 89
- Tax Reform Act of 1986,24
- Taxes
- congressional options for structuring coherent policies concerning, 24-25
 - R&D financing influenced by, 64-67
- Technology transfer
- restructuring, 167
 - U.S. policy concerning, 166-167, 168
- Thailand
- food exports by, 112
 - seed company subsidiaries in, 108
- Third-party payers, pharmaceutical cost-containment and, 83-84
- Third World. See Developing countries; Newly Industrializing Countries
- Tissue plasminogen activator (tPA)
- FDA regulatory decision on, 90
 - See *also* Pharmaceuticals
- Toxic Substances Control Act of 1976 (TSCA), EPA regulation of micro-organisms under, 16,23, 179, 180, 181
- Toxic Waste
- biotechnology's use in treating, 129
 - cleanup costs for, 131, 139-140
 - See *also* Pollution
- Toyo Soda 156
- Trade secrets. See Intellectual property protection, 205
- Training, Japanese need for foreign, 20
- Transgenic animals, 183-186,214-216,217
- Transgenic plants, 105-107, 182, 183
- Tsukuba, Japan, 104
- UCLA (University of California at Los Angeles), hybrid development by, 110
- Union for the Protection of New Varieties of Plants (UPOV), 24, 207,208,217,218
- United Kingdom (U.K.)
- biohydrometallurgy program in, 131
 - biotechnology-altered baker's yeast approved in, 107
 - biotechnology infrastructure in, 21
 - biotechnology policy in, 15,159-160,182, 193

- gene mapping work by, 104
- pharmaceutical industry in, 81,82,83,84,85
- R&D funding in, 83
- united states (Us.)
 - acquisition activity in, 85-89
 - agricultural biotechnology applications in, 108, 112
 - biohydrometallurgy program, 131
 - biotechnology policy in, 14,15-16,152,161-167
 - chemical industry in, 10, 122-123, 124
 - commercialization trends in, 3, 19-20, 165
 - cooperative research in, 164-167
 - drug approval process in, 75,76-77,101
 - environmental cleanup in, 131, 136
 - financial situation of biotechnology companies in, 48-50,51
 - historical view of commercial biotechnology in, 45-48
 - intellectual property variety and protection in, 16-18, 19,93, 203-205
 - patent policy in, 93,209-210
 - pharmaceutical industry characteristics and trends in, 81,82, 83,85-89,93
 - research funding in, 3,21-22,83, 111-112
 - strategic alliances' use in, 88-89
 - university-industry research agreements in, 164-165, 167
- Universities
 - congressional options for improving industrial relationships with, 24
 - hybrid development by, 110
 - relationship with industry of, 164-165, 167
 - role of Japan's national, 154-155
 - See *also* individual universities
- Upjohn Co., The, 89, 109
- U.S. Department of Agriculture (USDA)
 - basic research funding by, 3,21-22,83, 111
 - field test estimate by, 112, 113
 - PVPA administration by, 10
- Vaccines. See Pharmaceuticals
- Venture capital
 - financing in the United States, 3-6,7,39,50-51
 - role of, in Europe and Japan, 40,51-53
 - trends in availability to DBCs, 3-6,7
 - See *also* Costs; Economics; Financing
- Virus-Serum-Toxin Act, 178, 184
- Volvo, 109
- wall Street**
 - analyses of biotechnology firms, 6,7,49-50
 - effects of regulatory decisions on, 90
 - See *also*, "Black Monday"
- Watson, James D., 31
- Wellcome Foundation Ltd., The, 82
- Wisconsin, bST moratorium in, 102, 191
- World Intellectual Property Organization (WIPO), patent harmonization effort by, 23-24,207,217-218,234
- World War II, 73
- Wyngaarden, James, 164
- Xoma Corp., 79,84,85,89**

Other Related OTA Reports

- . *Ownership of Human Tissues and Cells—Special Report*
OTA-BA-337, March 1987; 176p.
GPO stock #052-003-01060-7; \$7.50 per copy
NTIS order #PB 87-207536
- . *Public Perceptions of Biotechnology*
OTA-BP-BA-45, May 1987; 136p.
NTIS order #PB 87-207544
- *Field-Testing Engineered organisms: Genetic and Ecological Issues—Special Report*
OTA-BA-350, May 1988; 160p.
NTIS order #PB 88-214101
- *U.S. Investment in Biotechnology—Special Report*
Free summary available from OTA
OTA-BA-360, July 1988; 304p.
NTIS order #PB 88-246939
- *Patenting Life—Special Report*
OTA-BA-370, April 1989; 204p.
GPO stock #052-003-01 137-9; \$8.50 per copy
NTIS order #PB 89-1% 612
- *Commercial Biotechnology: An International Analysis*
OTA-BA-218, January 1984; 616p.
NTIS order #PB 84-173608
- *Impacts of Applied Genetics: Micro-Organisms, Plants, and Animals*
OTA-HR-132, April 1981; 332p.
NTIS order #PB 81-206609.
- *Mapping Our Genes: Genome Projects—How Big? How Fast?*
OTA-BA-373, April 1988; 232p.
NTIS order #PB 88-212402

NOTE: Reports are available from the U.S. Government Printing Office, Superintendent of Documents, Dept. 33, Washington, DC 20402-9325, (202) 783-3238; and/or the National Technical Information Service, 5285 Port Royal Road, Springfield, VA 22161-0001, (703) 487-4650.